Press Releases
Recordati to participate at the Italian Investor Conference in London
Milan, 11 June 2009 – Recordati will be meeting investors at the Italian Investor Conference organized by Borsa Italiana which will take place in London on the 23rd and 24th of June at the London Stock Exchange (10 Paternoster Square).
Info and registration at:
Borsa Italiana – Primary Markets
Large Cap Team Continental Europe
Tel +39 02
72426034
italianinvestorconference@borsaitaliana.it
Recordati, established in 1926, is a
European pharmaceutical group, listed on the Italian Stock Exchange
(Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271),with a
total staff of over 2,900, dedicated to the research, development,
manufacturing and marketing of pharmaceuticals. It has headquarters
in Milan, Italy, operations in the main European countries, and a
growing presence in the new markets of Central and Eastern
Europe. A European field force of over 1,400 medical
representatives promotes a wide range of innovative
pharmaceuticals, both proprietary and under license, in a number of
therapeutic areas including a specialized business dedicated to
treatments for rare diseases. Recordati’s current and growing
coverage of the European pharmaceutical market makes it a partner
of choice for new product licenses from companies which do not have
European marketing organizations. Recordati is committed to
the research and development of new drug entities within the
cardiovascular and urogenital therapeutic areas and of treatments
for rare diseases. Consolidated revenue for 2008 was €
689.6 million, operating income was € 144.7 million and net
income was € 100.4 million.
For further information:
Recordati website: www.recordati.com
| Investor Relations Marianne Tatschke (39)0248787393 e-mail: inver@recordati.it |
Media Relations Claudio Rossetti (Echo Comunicazione d'Impresa) (39)02 62694736 e-mail: crossetti@echocom.it |
Statements contained in this release, other than historical facts, are "forward-looking statements" (as such term is defined in the Private Securities Litigation Reform Act of 1995). These statements are based on currently available information, on current best estimates, and on assumptions believed to be reasonable. This information, these estimates and assumptions may prove to be incomplete or erroneous, and involve numerous risks and uncertainties, beyond the Company’s control. Hence, actual results may differ materially from those expressed or implied by such forward-looking statements. All mentions and descriptions of Recordati products are intended solely as information on the general nature of the company’s activities and are not intended to indicate the advisability of administering any product in any particular instance.
